Details of the Drug

General Information of Drug (ID: DM3AD65)

Drug Name
EGFR806-specific CAR T cell
Indication
Disease Entry ICD 11 Status REF
Atypical teratoid/rhabdoid tumour 2A00.1Y Phase 1 [1]
Choroid plexus carcinoma 2A02.12 Phase 1 [1]
Ependymoma 2A00.0Y Phase 1 [1]
Gastric adenocarcinoma 2B72 Phase 1 [1]
Germ cell tumour 2C80.2 Phase 1 [1]
Glioma 2A00.0 Phase 1 [1]
Medulloblastoma 2A00.10 Phase 1 [1]
Pineoblastoma 2A00.20 Phase 1 [1]
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D0I7ZH

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN CAR-T-Cell-Therapy [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Brainstem tissue
The Studied Disease Glioma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Epidermal growth factor receptor (EGFR) DTT EGFR 2.09E-05 0.4 190.08
Epidermal growth factor receptor (EGFR) DTT EGFR 6.32E-04 0.39 1.69
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
2 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
3 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
4 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
5 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
6 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
8 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
9 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
10 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).